Alcoholic liver diease
Conditions
Interventions
Case series:Nil
Sponsors
Beijing Ditan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The gut microbiota profile in patients with alcoholic cirrhosis: Experimental group: (1) alcoholic cirrhosis patients diagnosed in our hospital were selected, and the diagnosis was in line with the diagnostic criteria of "guidelines for diagnosis and treatment of alcoholic liver disease" in China: long-term drinking history (generally more than 5 years, ethanol equivalent male >=40g/d, female >=20g/d); Signs of cirrhosis (such as rough surface, reduced liver volume, enlarged spleen) were found on imaging. Instantaneous elastography was greater than 12.5kpa); (2) the patient can understand and sign the written informed consent and voluntarily join this study; (3) Aged 18-70 years old. Healthy control group: 1) meet the world health organization's definition of health (i.e. in good physical, mental and social condition); 2) liver function and other related tests showed no abnormality; 2. Effects of individualized intestinal microecological intervention on intestinal microecological characteristics and short-term prognosis of patients with alcoholic cirrhosis: Experimental group: (1) alcoholic cirrhosis patients diagnosed in our hospital were selected, and the diagnosis was in line with the diagnostic criteria of "guidelines for diagnosis and treatment of alcoholic liver disease" in China: long-term drinking history (generally more than 5 years, ethanol equivalent male >=40g/d, female >=20g/d); Signs of cirrhosis (such as rough surface, reduced liver volume, enlarged spleen) were found on imaging. Instantaneous elastography was greater than 12.5kpa); (2) Aged 18-70 years old; (3) the patient can understand and sign the written informed consent and voluntarily join this study; (4) Patients with cirrhosis are in decompensated stage, child-pugh grade is B or C, or patients with esophageal and gastric varicose bleeding, ascites, and/or hepatic encephalopathy.
Exclusion criteria
Exclusion criteria: 1. Experimental group: (1) patients with cirrhosis caused by hepatitis b, c, drugs, autoimmunity and other causes; (2) patients with primary liver cancer; (3) patients with antifungal, antibacterial drugs or oral intestinal microecological preparations within 1 month; (4) patients with bacterial and fungal infections within one month; (5) patients infected with human immunodeficiency virus; (6) Other digestive tract diseases that may affect intestinal microecology; (7) uncontrolled kidney, heart, lung, vascular, neurological, digestive (pancreatitis or pancreatic cancer), metabolic diseases (diabetes, thyroid and adrenal diseases), immunodeficiency diseases or cancer; (8) Medication abuse or drug abuse history patients; (9) pregnant and lactating female patients; (10) The patients who are unable to attend. 2. Healthy control group: (1) Patients with HBV infection or other diseases; (2) patients who have used or are using antibiotics, prebiotics, probiotics or traditional Chinese medicine preparations within 1 week.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cirrhosis dysbiosis ratio; | — |
Contacts
Public ContactHuichun Xing
Beijing Ditan Hospital, Capital Medical University,Beijing
Outcome results
None listed